Discovery of a Potent Dual Son of Sevenless 1 (SOS1) and Epidermal Growth Factor Receptor (EGFR) Inhibitor for the Treatment of Prostate Cancer
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.3c02433 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Lufeng Zheng und 12 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, China Pharmaceutical University, Nanjing 211198, China. Hauptthemen laut MEDLINE: ErbB Receptors, Prostatic Neoplasms, SOS1 Protein, Antineoplastic Agents. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: China Pharmaceutical University, National Natural Science Foundation of China, Priority Academic Program Development of Jiangsu Higher Education Institutions.
Abstract (Originalsprache)
Multitarget medications represent an appealing therapy against the disease with multifactorial abnormalities─cancer. Therefore, simultaneously targeting son of sevenless 1 (SOS1) and epidermal growth factor receptor (EGFR), two aberrantly expressed proteins crucial for the oncogenesis and progression of prostate cancer, may achieve active antitumor effects. Here, we discovered dual SOS1/EGFR-targeting compounds via pharmacophore-based docking screening. The most prominent compound SE-9 exhibited nanomolar inhibition activity against both SOS1 and EGFR and efficiently suppressed the phosphorylation of ERK and AKT in prostate cancer cells PC-3. Cellular assays also revealed that SE-9 displayed strong antiproliferative activities through diverse mechanisms, such as induction of cell apoptosis and G1 phase cell cycle arrest, as well as reduction of angiogenesis and migration. Further in vivo findings showed that SE-9 potently inhibited tumor growth in PC-3 xenografts without obvious toxicity. Overall, SE-9 is a novel dual-targeting SOS1/EGFR inhibitor that represents a promising treatment strategy for prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, China Pharmaceutical University, Nanjing 211198, China.
- School of Life Science and Technology, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing 211198, China.
- Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 211198, China.
- Department of Analytical Chemistry, School of Sciences, China Pharmaceutical University, Nanjing 210009, China.
- Department of Pharmacy, Taizhou School of Clinical Medicine, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou 225300, China.
- Taizhou School of Clinical Medicine, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou 225300, China.
ORCID-Profile: Lufeng Zheng, Pierre Dramou, Yang Zhou, Miao-Miao Niu
Förderung
- China Pharmaceutical University
- National Natural Science Foundation of China
- Priority Academic Program Development of Jiangsu Higher Education Institutions
- Changzhou Health Committee
Zitieren
APA
Zheng, L., Zhang, Y., Mei, S., Xie, T., Zou, Y., Wang, Y., Jing, H., Xu, S., Dramou, P., Xu, Z., Li, J., Zhou, Y., & Niu, M. M. (2024). Discovery of a Potent Dual Son of Sevenless 1 (SOS1) and Epidermal Growth Factor Receptor (EGFR) Inhibitor for the Treatment of Prostate Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c02433
Vancouver
Zheng L, Zhang Y, Mei S, Xie T, Zou Y, Wang Y, et al. Discovery of a Potent Dual Son of Sevenless 1 (SOS1) and Epidermal Growth Factor Receptor (EGFR) Inhibitor for the Treatment of Prostate Cancer. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.3c02433
BibTeX
@article{Zheng2024,
author = {Zheng, Lufeng and Zhang, Yuxin and Mei, Shuang and Xie, Tianyuan and Zou, Yunting and Wang, Yuting and Jing, Han and Xu, Shengtao and Dramou, Pierre and Xu, Zhen and Li, Jindong and Zhou, Yang and Niu, Miao-Miao},
title = {Discovery of a Potent Dual Son of Sevenless 1 (SOS1) and Epidermal Growth Factor Receptor (EGFR) Inhibitor for the Treatment of Prostate Cancer},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.3c02433}
}
EUVIMED